Splash Beverage partners with Lupvindol to advance CannEpil via FDA veterinary pathway

• Splash Beverage Group signed a development and collaboration deal with Lupvindol Biosciences to advance CannEpil via the FDA veterinary drug pathway.
• Program targets companion-animal oncology, chronic pain management, with initial focus on dogs.
• Lupvindol to run scientific development, product work, FDA regulatory strategy, including the INAD process, toward potential conditional approval.
• Splash to fund milestones, lead commercialization strategy, retain ownership of study data, regulatory submissions, new IP, licensing rights.
• Lupvindol to absorb the annual FDA sponsor fee through conditional approval unless sponsorship is transferred.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Splash Beverage Group Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608050830PRIMZONEFULLFEED9804153) on August 05, 2026, and is solely responsible for the information contained therein.